This trial is testing a new drug called Toripalimab to see if it is safe and effective for treating advanced cancers. The trial will also look at the drug's effects on the immune system and overall survival.
1 Primary · 4 Secondary · Reporting Duration: Every 8 weeks (Part A) or every 9 weeks (Part B) through study completion, an average of 1 year
198 Total Participants · 4 Treatment Groups
Primary Treatment: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: